Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Z Piotrowska, MJ Niederst, CA Karlovich, HA Wakelee…�- Cancer discovery, 2015 - AACR
Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied�…
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied�…
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Z Piotrowska, MJ Niederst, CA Karlovich…�- Cancer�…, 2015 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Rociletinib is a third-generation EGFR inhibitor
active in lung cancers with T790M, the gatekeeper mutation underlying most first-generation�…
active in lung cancers with T790M, the gatekeeper mutation underlying most first-generation�…
[PDF][PDF] Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR�…
Z Piotrowska, MJ Niederst, CA Karlovich, HA Wakelee… - 2015 - academia.edu
Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied�…
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied�…
[PDF][PDF] Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third Generation EGFR�…
Z Piotrowska, MJ Niederst, CA Karlovich… - researchgate.net
Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied�…
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied�…
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Z Piotrowska, MJ Niederst, CA Karlovich…�- Cancer�…, 2015 - pubmed.ncbi.nlm.nih.gov
Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied�…
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied�…
[HTML][HTML] Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third Generation EGFR�…
Z Piotrowska, MJ Niederst, CA Karlovich…�- Cancer�…, 2015 - ncbi.nlm.nih.gov
Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied�…
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied�…
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
Z Piotrowska, MJ Niederst, CA Karlovich…�- Cancer�…, 2015 - europepmc.org
Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied�…
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied�…
[PDF][PDF] Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR�…
Z Piotrowska, MJ Niederst, CA Karlovich, HA Wakelee… - 2015 - academia.edu
Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied�…
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied�…